BRAF and neoplasm: MEK is a mitogen-activated protease downstream of BRAF [75], and MEK inhibitors reduce the activity of the MAPK signaling pathway by blocking the expression of MEK genes located downstream of BRAF genes and RAS genes, thereby inhibiting tumor cell proliferation [76].